Galapagos receives EU2.3 million IWT grant for fibrosis research
February 03 2014 - 1:35AM
Galapagos NV (Euronext: GLPG) announced today that it has
been awarded a €2.3 million grant for research in
fibrosis from the Flemish agency for Innovation by Science and
Technology (IWT). The goal of this 2-year
project is to create a new research platform by integrating
knowledge from a range of fibrotic diseases, including lung,
kidney, liver, and skin fibrosis. This new platform will
support Galapagos' efforts to develop novel drug candidates in
fibrosis.
Galapagos has a fully proprietary portfolio of
fibrosis drug targets and molecules. The major aim of this
IWT grant is to deliver a comprehensive fibrosis research platform,
building on existing tools and considerable expertise within
Galapagos and a number of academic laboratories. By
integrating data obtained from pre-clinical and clinical research
in several fibrotic diseases with similar root causes, Galapagos
aims to create a unique fibrosis research environment, allowing for
better selection of targets and molecules for the design of novel
treatments in this area. Academic partners for the project
include Prof Dr Wuyts (Pneumology, KU Leuven), Prof Dr Naesens and
Prof Dr Kuypers (Nephrology, KU Leuven), Prof Dr Van Vlierberghe
(Hepatology, U Ghent), Prof Dr F. De Keyser and Dr Smith
(Scleroderma, U Gent) and Prof van Grunsven (Hepatology, VU
Brussels).
"Galapagos is very pleased with this financial
support from the IWT for our research in fibrosis, an area with
very high unmet patient need and one in which Galapagos already has
performed ground-breaking work," said Dr Piet Wigerinck, Chief
Scientific Officer of Galapagos.
About Fibrosis Fibrosis is
characterized by the development of excess connective tissue,
leading to diminished organ function and potentially death.
Fibrosis can affect various organs and tissues including
kidney, lung, liver, heart, bone marrow, and skin. Fibrosis
accounts for an estimated 45% of deaths in the Western world[i],
and the therapeutic options available for patients remain very
limited.
About IWT The agency for
Innovation by Science and Technology (abbreviated as IWT) is the
government agency founded in 1991 by the Flemish Government to
support technological innovation projects in Flanders. Each
year IWT distributes about €300 million in subsidies for innovation
projects to companies, organizations, research and educational
institutions in Flanders. In addition to financial support,
IWT also assists companies by, for instance helping them find the
right information or the right partners at home or abroad,
providing assistance with the preparation of projects for European
programmes and with technology transfer throughout Europe.
IWT also has an important coordination mandate aimed at
promoting close cooperation among all the actors involved in
technological innovation in Flanders. For more information,
please visit http://www.iwt.be or call +32 2 432 42 00.
About Galapagos Galapagos
(Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising of six Phase 2
studies (three led by GSK), one Phase 1 study, six pre-clinical,
and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. AbbVie and Galapagos signed an agreement in CF where
they work collaboratively to develop and commercialize oral drugs
that address two mutations in the CFTR gene, the G551D and F508del
mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor in
Phase 2 in ulcerative colitis, psoriasis, and lupus, GSK2586184
(formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).
GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically
for the treatment of IBD; this program is currently in a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class
molecule that targets inflammatory disorders and has completed
Phase 1 studies. The Galapagos Group, including fee-for-service
companies BioFocus, Argenta and Fidelta, has around 800 employees
and operates facilities in five countries, with global headquarters
in Mechelen, Belgium. Further information at:
www.glpg.com
Contact
For media and investor inquiries: Elizabeth
Goodwin, Head of Corporate Communications & Investor Relations
Tel: +31 6 2291 6240 ir@glpg.com For business
development inquiries: Andre Hoekema, Senior VP Corporate
Development Tel: +31 71 7506 700 bd@glpg.com
Galapagos forward-looking
statements This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation. [i] Friedman et al,
2013
Galapagos receives €2.3 million IWT grant for fibrosis research
http://hugin.info/133350/R/1758331/594443.pdf
HUG#1758331
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jul 2023 to Jul 2024